Credit Suisse Keeps $60 PT on Ventyx Biosciences Inc (VTYX), 'deucravacitinib’s clean label sets a highly favorable precedent for the TYK2i class'
Tweet Send to a Friend
Credit Suisse analyst Tiago Fauth reiterated an Outperform rating and $63.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
